GILEAD SCIENCES INC

Gilead Sciences’ steady Q4 results show modest revenue growth, a robust hepatitis‑B launch, and a diversified Phase III pipeline that may drive future gains.

Gilead’s FDA acceptance of Yeztugo’s sNDA marks a key milestone for its once‑weekly HIV PrEP, while insider share sales confirm routine liquidity activity and highlight investor confidence.

Gilead Sciences Q1 2026 earnings hit $1.34 EPS, yet analyst targets swing from $90 to $135 as new hepatitis‑B and immuno‑oncology candidates promise upside, while patent expirations loom.

Gilead Sciences advances obeldesivir for Ebola and tro delvy for triple‑negative breast cancer, showing promise in regulatory approvals and clinical trials.

Gilead Sciences shares executive equity awards, updated financials and a roadmap for next‑gen antivirals, patent strategy, and M&A moves to stay ahead of pricing pressures and rivals.

Gilead’s Q4 2025 earnings reveal steady antiviral revenue and rapid growth in oncology assets like Gidea, impacting investors and patient access in biopharma.

Gilead’s share dip reveals how short‑term volatility intertwines with long‑term CAR‑T strategy, amid rising oral myeloma agents and heavy peer investments.

Gilead’s modest market gains come as it expands the long‑acting HIV‑prevention drug lenacapavir, partnering with GFATM to reach millions of high‑risk people worldwide.

Gilead Sciences’ $200‑$250 M purchase of Tubulis expands its ADC portfolio, secures patent protection, and boosts oncology revenue with a 23 % IRR.

Gilead’s $2.2 B acquisition of Ouro Medicines expands its portfolio into high‑growth autoimmune disease therapy, promising diversified revenue, stronger R&D and above‑average ROIC.